Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico

medRxiv(2022)10.1101/2022.02.08.22270676Source: DataRank Database

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico is a research paper published in medRxiv (2022). On theSindex it has a DataRank of 1.1. It has been cited 26 times, with 21 citing works in its 1-hop citation network.

N/A

1.1DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access26 citations · 21 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04871737

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: greenTopics (22)IDs (PubMed, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 47%Citation Network 53%

Base Score Contribution

0.494

From this paper's citation signal

Citation Network Contribution

0.557

From 15 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 21 citers.

Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization
Nature2023137 citations47 referencesContributes 0.105
Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters
Vaccine20227 citations22 referencesContributes 0.095
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
EBioMedicine2022150 citations54 referencesContributes 0.093
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled and Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults
Vaccines202314 citations30 referencesContributes 0.090
Mucosal vaccines for SARS-CoV-2: triumph of hope over experience
EBioMedicine202396 citations95 referencesContributes 0.048

Authors (33)

Martha Torres ORCID,Luis Enrique Soto-Ramírez ORCID,Juan J. Calva ORCID,Patricio Santillán‐Doherty ORCID,Dora Eugenia Carranza-Salazar

Live enrichment

PubMed:35169806 OpenAlex:https://openalex.org/W4211106360

National Institutes of Health

Grant: 5P01AI097092-04

Monoclonal Antibody Technology Core

National Institutes of Health

Grant: 3R01AI145870-02S1

Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection

greenLicense: cc-by-nc-nd

repositoryhttps://www.medrxiv.org/content/medrxiv/early/2022/02/09/2022.02.08.22270676.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2022.02.08.22270676

repositoryhttps://doi.org/10.1101/2022.02.08.22270676

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35169806

Fields of Study

SARS-CoV-2 and COVID-19 ResearchVirology and Viral DiseasesVaccine Coverage and Hesitancy0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

ImmunogenicityInterimNasal administrationMedicineVirologyCoronavirus disease 2019 (COVID-19)Interim analysisNewcastle diseaseRandomized controlled trialVirusDiseaseImmunologyAntibodyInternal medicineInfectious disease (medical specialty)Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Related Papers (2)

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

N/A

1.2DataRank · unranked

Cell(2020)

co-cited

10.1016/j.cell.2020.05.015

SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo

Nature(2022)

co-cited

10.1038/s41586-022-04479-6

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (33)

Funding (2 grants)

Open Access

Topics

Annotations (Europe PMC)

Related Papers (2)